Establishing best practice in the Australian haematology setting for the use of chimeric antigen receptor T-cell therapy for relapsed and refractory lymphoma

IF 1.8 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL
Michael Dickinson, Nicole O'Leary, Nada Hamad, Tara Cochrane, P. Joy Ho, Chan Y. Cheah, David Bishop, Gareth P. Gregory, Jason Butler, Allison Barraclough
{"title":"Establishing best practice in the Australian haematology setting for the use of chimeric antigen receptor T-cell therapy for relapsed and refractory lymphoma","authors":"Michael Dickinson,&nbsp;Nicole O'Leary,&nbsp;Nada Hamad,&nbsp;Tara Cochrane,&nbsp;P. Joy Ho,&nbsp;Chan Y. Cheah,&nbsp;David Bishop,&nbsp;Gareth P. Gregory,&nbsp;Jason Butler,&nbsp;Allison Barraclough","doi":"10.1111/imj.16544","DOIUrl":null,"url":null,"abstract":"<p>Autologous CD19 chimeric antigen receptor T (CAR T)-cell therapies have significantly improved clinical outcomes for many patients with relapsed and refractory (R/R) lymphoma. However, the process of delivering CAR T-cell therapy is specialised and complex, in part due to specific post-infusion toxicities. Several CAR T-cell products are now available in Australia, although not all states have treatment centres. In this review, we aim to define best practice for the referral and treatment of patients with R/R B-cell lymphoma with CAR T-cell therapy in Australia. We outline the processes for referral, optimal patient selection and best practice in the management of patients receiving CAR T cells.</p>","PeriodicalId":13625,"journal":{"name":"Internal Medicine Journal","volume":"55 S2","pages":"4-27"},"PeriodicalIF":1.8000,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Internal Medicine Journal","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/imj.16544","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Autologous CD19 chimeric antigen receptor T (CAR T)-cell therapies have significantly improved clinical outcomes for many patients with relapsed and refractory (R/R) lymphoma. However, the process of delivering CAR T-cell therapy is specialised and complex, in part due to specific post-infusion toxicities. Several CAR T-cell products are now available in Australia, although not all states have treatment centres. In this review, we aim to define best practice for the referral and treatment of patients with R/R B-cell lymphoma with CAR T-cell therapy in Australia. We outline the processes for referral, optimal patient selection and best practice in the management of patients receiving CAR T cells.

在澳大利亚血液学环境中建立使用嵌合抗原受体t细胞治疗复发和难治性淋巴瘤的最佳实践
自体CD19嵌合抗原受体T (CAR - T)细胞疗法显著改善了许多复发和难治性(R/R)淋巴瘤患者的临床结果。然而,提供CAR - t细胞治疗的过程是专门的和复杂的,部分原因是由于特定的输注后毒性。尽管不是所有的州都有治疗中心,但目前在澳大利亚有几种CAR - t细胞产品。在这篇综述中,我们的目标是确定在澳大利亚用CAR - t细胞疗法转诊和治疗R/R b细胞淋巴瘤患者的最佳实践。我们概述了在接受CAR - T细胞治疗的患者的转诊过程、最佳患者选择和最佳实践。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Internal Medicine Journal
Internal Medicine Journal 医学-医学:内科
CiteScore
3.50
自引率
4.80%
发文量
600
审稿时长
3-6 weeks
期刊介绍: The Internal Medicine Journal is the official journal of the Adult Medicine Division of The Royal Australasian College of Physicians (RACP). Its purpose is to publish high-quality internationally competitive peer-reviewed original medical research, both laboratory and clinical, relating to the study and research of human disease. Papers will be considered from all areas of medical practice and science. The Journal also has a major role in continuing medical education and publishes review articles relevant to physician education.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信